RhyGaze secured $86 million in a Series A financing round, which will be used to further the development of the company’s lead candidate gene therapy for optogenetic vision restoration, according to a press release.
GV led the financing round. Contributors included Arch Venture Partners and F-Prime Capital along with founding investors BioGeneration Ventures and Novartis Venture Fund.
The funding will support early activities for the gene therapy, including formal pharmacology and toxicology testing, assessment of potential clinical endpoints, and a first-in-human clinical trial to